The Quest for Circulating Biomarkers in Neuroendocrine Neoplasms: a Clinical Perspective-Reference-Cited by-同舟云学术

The Quest for Circulating Biomarkers in Neuroendocrine Neoplasms: a Clinical Perspective

Published:2023-11-22 Issue:12 Volume:24 Page:1833-1851
ISSN:1527-2729
Container-title:Current Treatment Options in Oncology
language:en
Short-container-title:Curr. Treat. Options in Oncol.

Author:

Mariën Laura^ORCID,Islam Odeta,Chhajlani Siddharth^ORCID,Lybaert Willem,Peeters Marc^ORCID,Van Camp Guy^ORCID,Op de Beeck Ken^ORCID,Vandamme Timon^ORCID

Funder

Research Foundation Flanders

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11864-023-01147-3.pdf

Reference111 articles.

1. Rizen EN, Phan AT. Neuroendocrine tumors: a relevant clinical update. Curr Oncol Rep. 2022;24(6):703–14. https://doi.org/10.1007/s11912-022-01217-z.

2. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42. https://doi.org/10.1001/jamaoncol.2017.0589.

3. Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia (New York, NY). 2017;19(12):991–1002. https://doi.org/10.1016/j.neo.2017.09.002.

4. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (New York, NY). 2011;331(6021):1199–203. https://doi.org/10.1126/science.1200609.

5. Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33(1):115–54. https://doi.org/10.1007/s12022-022-09708-2.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum concentrations of chromogranin A, serotonin and natriuretic peptide are decreased in patients with neuroendocrine tumors with overweight and obesity compared to healthy donors;Almanac of Clinical Medicine;2024-09-10

2. Clinicopathological and molecular differences between stage IV screen-detected and interval colorectal cancers in the Flemish screening program;Frontiers in Oncology;2024-09-02

3. NETest in advanced high‐grade gastroenteropancreatic neuroendocrine neoplasms;Journal of Neuroendocrinology;2024-06-27

4. Biochemical Markers for Neuroendocrine Tumors: Traditional Circulating Markers and Recent Development—A Comprehensive Review;Diagnostics;2024-06-18

5. Improvements and future perspective in diagnostic tools for neuroendocrine neoplasms;Expert Review of Endocrinology & Metabolism;2024-06-05